Patients with advanced or metastatic disease receive a cisplatin-based combination therapy if they carry neither an epithelial growth factor receptor (EGFR) nor an anaplastic lymphoma kinase (ALK) mutation [1]. Here, ALK is linked to metastatic neoplasm.